These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28018847)

  • 1. Uncertainty and innovation: Understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments.
    Isasi R; Rahimzadeh V; Charlebois K
    Appl Transl Genom; 2016 Dec; 11():27-39. PubMed ID: 28018847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Workshop to address gaps in regulation of minimally manipulated autologous cell therapies for homologous use in Canada.
    Chisholm J; von Tigerstrom B; Bedford P; Fradette J; Viswanathan S
    Cytotherapy; 2017 Dec; 19(12):1400-1411. PubMed ID: 28964743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of heterogeneous primary human cartilage-derived cell population using non-invasive live-cell phase-contrast time-lapse imaging.
    Mantripragada VP; Tan KL; Vasavada S; Bova W; Barnard J; Muschler GF
    Cytotherapy; 2021 Jun; 23(6):488-499. PubMed ID: 33092987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic distribution of conversion therapy prevalence in Canada. Findings from a national cross-sectional survey, 2020.
    Tiwana A; Salway T; Schillaci-Ventura J; Watt S
    F1000Res; 2023; 12():844. PubMed ID: 38434633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
    J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical limb ischemia: thrombogenic evaluation of two autologous cell therapy products and biologic profile in treated patients.
    Tournois C; Pignon B; Sevestre MA; Djerada Z; Capiod JC; Poitevin G; Delloup AM; Nguyen P
    Transfusion; 2015 Nov; 55(11):2692-701. PubMed ID: 26222701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current practices and reform proposals for the regulation of advanced medicinal products in Canada.
    Viswanathan S; Bubela T
    Regen Med; 2015; 10(5):647-63. PubMed ID: 26237706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Business model configuration and dynamics for technology commercialization in mature markets.
    Flammini S; Arcese G; Lucchetti MC; Mortara L
    Br Food J; 2017; 119(11):2340-2358. PubMed ID: 29720738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol.
    Pettitt D; Arshad Z; Davies B; Smith J; French A; Cole D; Bure K; Dopson S; DiGiusto D; Karp J; Reeve B; Barker R; Holländer G; Brindley D
    Syst Rev; 2017 Jun; 6(1):120. PubMed ID: 28651620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryopreserved Placental Membrane Allograft Reduces the Likelihood of Developing a New or Recurring Foot Ulcer and All-Cause Mortality in Diabetic Patients When Compared with Other Cellular- and Tissue-Based Products.
    DaVanzo J; Hartzman A; Surfield C; Dobson A
    Adv Wound Care (New Rochelle); 2023 Apr; 12(4):169-176. PubMed ID: 35262428
    [No Abstract]   [Full Text] [Related]  

  • 11. The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan.
    Perampaladas K; Masum H; Kapoor A; Shah R; Daar AS; Singer PA
    BMC Int Health Hum Rights; 2010 Dec; 10 Suppl 1(Suppl 1):S11. PubMed ID: 21144071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transpedicular aspiration of osteoprogenitor cells from the vertebral body: progenitor cell concentrations affected by serial aspiration.
    McLain RF; Boehm CA; Rufo-Smith C; Muschler GF
    Spine J; 2009 Dec; 9(12):995-1002. PubMed ID: 19837006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manufacturing road map for tissue engineering and regenerative medicine technologies.
    Hunsberger J; Harrysson O; Shirwaiker R; Starly B; Wysk R; Cohen P; Allickson J; Yoo J; Atala A
    Stem Cells Transl Med; 2015 Feb; 4(2):130-5. PubMed ID: 25575525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perspectives on Challenges to Cell Therapy Development in Taiwan: Strengthening Evidential Standards and Ways Forward.
    Abolarinwa BA; Shaw MK; Lee CH
    Front Bioeng Biotechnol; 2021; 9():789043. PubMed ID: 34976978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategy for an abbreviated in-house qualification of a commercially available Rapid Microbiology Method (RMM) for canadian regulatory approval.
    Chisholm J; Bhatt S; Chaboureau A; Viswanathan S
    Cytotherapy; 2017 Dec; 19(12):1529-1536. PubMed ID: 29066052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expansion processes for cell-based therapies.
    Scibona E; Morbidelli M
    Biotechnol Adv; 2019 Dec; 37(8):107455. PubMed ID: 31629791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
    Azuma K; Yamanaka S
    Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.